These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 26106454)

  • 1. Withdrawal-Emergent Dyskinesias following Varenicline Therapy.
    Toffey BA; Rabin M; Kurlan R
    Open Neurol J; 2015; 9():7-8. PubMed ID: 26106454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Varenicline on Tardive Dyskinesia: A Pilot Study.
    Caroff SN; Gutman AR; Northrop J; Leong SH; Berkowitz RM; Campbell EC
    Clin Psychopharmacol Neurosci; 2021 May; 19(2):355-360. PubMed ID: 33888664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nicotine receptor partial agonists for smoking cessation.
    Cahill K; Stead LF; Lancaster T
    Cochrane Database Syst Rev; 2011 Feb; (2):CD006103. PubMed ID: 21328282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nicotine receptor partial agonists for smoking cessation.
    Cahill K; Stead LF; Lancaster T
    Cochrane Database Syst Rev; 2010 Dec; (12):CD006103. PubMed ID: 21154363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nicotine receptor partial agonists for smoking cessation.
    Cahill K; Stead LF; Lancaster T
    Cochrane Database Syst Rev; 2008 Jul; (3):CD006103. PubMed ID: 18646137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nicotine receptor partial agonists for smoking cessation.
    Cahill K; Stead LF; Lancaster T
    Cochrane Database Syst Rev; 2012 Apr; (4):CD006103. PubMed ID: 22513936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Varenicline: a review of its use as an aid to smoking cessation therapy.
    Keating GM; Siddiqui MA
    CNS Drugs; 2006; 20(11):945-60. PubMed ID: 17044731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Varenicline: progress in smoking cessation treatment.
    Glover ED; Rath JM
    Expert Opin Pharmacother; 2007 Aug; 8(11):1757-67. PubMed ID: 17685891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.
    Jorenby DE; Hays JT; Rigotti NA; Azoulay S; Watsky EJ; Williams KE; Billing CB; Gong J; Reeves KR;
    JAMA; 2006 Jul; 296(1):56-63. PubMed ID: 16820547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Taking varenicline for smoking cessation: A rare cause of pulmonary thromboembolism with infarction.
    Lee SH; Yun SJ; Ryu S; Choi SW; Kim HJ; Kang TK; Oh SC; Cho SJ
    Am J Emerg Med; 2017 Jul; 35(7):1037.e3-1037.e6. PubMed ID: 28268112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Varenicline: for smoking cessation.
    Rao J; Shankar PK
    Kathmandu Univ Med J (KUMJ); 2009; 7(26):162-4. PubMed ID: 20071853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neural Signatures of Cognitive Flexibility and Reward Sensitivity Following Nicotinic Receptor Stimulation in Dependent Smokers: A Randomized Trial.
    Lesage E; Aronson SE; Sutherland MT; Ross TJ; Salmeron BJ; Stein EA
    JAMA Psychiatry; 2017 Jun; 74(6):632-640. PubMed ID: 28403383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up.
    Nides M; Oncken C; Gonzales D; Rennard S; Watsky EJ; Anziano R; Reeves KR
    Arch Intern Med; 2006 Aug 14-28; 166(15):1561-8. PubMed ID: 16908788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Smoking cessation efficacy and safety of varenicline, an alpha4beta2 nicotinic receptor partial agonist.
    Tonstad S
    J Cardiovasc Nurs; 2006; 21(6):433-6. PubMed ID: 17293731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid.
    Rollema H; Chambers LK; Coe JW; Glowa J; Hurst RS; Lebel LA; Lu Y; Mansbach RS; Mather RJ; Rovetti CC; Sands SB; Schaeffer E; Schulz DW; Tingley FD; Williams KE
    Neuropharmacology; 2007 Mar; 52(3):985-94. PubMed ID: 17157884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New insights on the effects of varenicline on nicotine reward, withdrawal and hyperalgesia in mice.
    Bagdas D; Alkhlaif Y; Jackson A; Carroll FI; Ditre JW; Damaj MI
    Neuropharmacology; 2018 Aug; 138():72-79. PubMed ID: 29860196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors.
    Mihalak KB; Carroll FI; Luetje CW
    Mol Pharmacol; 2006 Sep; 70(3):801-5. PubMed ID: 16766716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Procognitive effects of varenicline in the animal model of schizophrenia depend on α4β2- and α 7-nicotinic acetylcholine receptors.
    Potasiewicz A; Golebiowska J; Popik P; Nikiforuk A
    J Psychopharmacol; 2018 Dec; 33(1):269881118812097. PubMed ID: 30501536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zonisamide Reduces Withdrawal Symptoms But Does Not Enhance Varenicline-Induced Smoking Cessation.
    Dunn KE; Marcus TF; Kim C; Schroeder JR; Vandrey R; Umbricht A
    Nicotine Tob Res; 2016 May; 18(5):1171-9. PubMed ID: 26476459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation.
    Oncken C; Gonzales D; Nides M; Rennard S; Watsky E; Billing CB; Anziano R; Reeves K
    Arch Intern Med; 2006 Aug 14-28; 166(15):1571-7. PubMed ID: 16908789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.